Anavex Life Sciences (AVXL) Accounts Payables (2011 - 2025)

Anavex Life Sciences (AVXL) has 15 years of Accounts Payables data on file, last reported at $2.6 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 42.22% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2025 stood at $2.6 million (down 42.22% YoY), and the FY2025 full-year result was $4.2 million, down 55.86% from the prior year.
• Accounts Payables retreated to $2.6 million in Q4 2025, from $4.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $9.6 million in Q3 2024 to a low of $2.3 million in Q1 2025.
• A 5-year average of $4.4 million and a median of $4.2 million in 2021 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 138.68% in 2023 and slumped 55.86% in 2025, its largest moves.
• Tracing AVXL's Accounts Payables over 5 years: stood at $4.6 million in 2021, then grew by 14.1% to $5.3 million in 2022, then decreased by 18.84% to $4.3 million in 2023, then rose by 6.41% to $4.6 million in 2024, then slumped by 42.22% to $2.6 million in 2025.
• Business Quant data shows AVXL's Accounts Payables at $2.6 million in Q4 2025, $4.2 million in Q3 2025, and $6.7 million in Q2 2025.